Highlights
Profile claimed by owner
About
Cognition Restoring Treatment for Alzheimer’s Disease
MemoryPlus is pioneering an innovative treatment targeting Alzheimer’s-related cognitive decline, leveraging a novel mechanism of action (MOA). Its research is based on groundbreaking work from Prof. Shira Knafo, who discovered that the PTEN protein plays a critical role in memory decline by inhibiting neuronal activity. By disrupting the interaction between PTEN and PDZ domain proteins, the company has the potential to restore memory function.
Identity
| Name | MemoryPlus |
|---|---|
| Slug | memoryplus |
| Type / kind | startup |
| Source _id | QuKoplMq8CxcsjOFZCawpgtR1oS9VVDBXCeTms0duCYYWNCMI7U5Cd |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Rehovot |
| HQ address | Rehovot, Israel |
Web & social
| https://www.linkedin.com/company/105104554 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
alzheimers-diseasepharmaceuticalsbiotechnologytreatments
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}